BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 27.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,359 shares of the biotechnology company’s stock after acquiring an additional 10,086 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in BioCryst Pharmaceuticals were worth $284,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Fifth Third Bancorp raised its position in shares of BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. increased its position in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the period. JGP Global Gestao de Recursos Ltda. bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $64,000. MA Private Wealth acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $76,000. Finally, Great Valley Advisor Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 34.7% during the third quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 4,200 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ BCRX opened at $4.45 on Monday. The firm’s 50-day simple moving average is $4.93 and its 200 day simple moving average is $5.46. The stock has a market cap of $918.17 million, a P/E ratio of -3.77 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.